Hair Loss Following Omalizumab Therapy: A Systematic Review

Abstract

Keywords

hair loss alopecia areata telogen effluvium omalizumab systematic review

Get full access to this article

View all access options for this article.

References

Casale

Gimenez-Arnau

Bernstein

Holden

Zuberbier

Maurer

Omalizumab for patients with chronic spontaneous urticaria: a narrative review of current status. Dermatol Ther. 2023;13(11):2573-2588. doi:10.1007/s13555-023-01040-9

Busse

Corren

Lanier

, et al. Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. J Allergy Clin Immunol. 2001;108(2):184-190. doi:10.1067/mai.2001.117880

Jaromin

Wardzyńska

Off-label applications of omalizumab: current insights and perspectives. World Allergy Organ J. 2025;18(12):Article 101156. doi:10.1016/j.waojou.2025.101156

Okayama

Matsumoto

Odajima

Takahagi

Hide

Okubo

Roles of omalizumab in various allergic diseases. Allergol Int. 2020;69(2):167-177. doi:10.1016/j.alit.2020.01.004

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.06 MB